These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20171144)

  • 21. Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.
    Hoy SM
    CNS Drugs; 2013 Dec; 27(12):1125-42. PubMed ID: 24203890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures.
    Degiorgio CM
    Epilepsy Behav; 2010 Jul; 18(3):322-4. PubMed ID: 20570216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial.
    Shaibani A; Biton V; Rauck R; Koch B; Simpson J
    Eur J Pain; 2009 May; 13(5):458-63. PubMed ID: 18619874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents.
    Higgins GA; Breysse N; Undzys E; Kuo C; Joharchi N; Derksen DR; Xin T; Isaac M; Slassi M
    Eur J Pharmacol; 2009 Dec; 624(1-3):1-9. PubMed ID: 19818346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electroencephalographic and Electrocardiographic Effect of Intravenous Lacosamide in Refractory Focal Epilepsy.
    Huang CW; Brown S; Pillay N; Campo MD; Tellez-Zenteno J; McLachlan RS
    J Clin Neurophysiol; 2018 Sep; 35(5):365-369. PubMed ID: 29851686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lacosamide for the treatment of epilepsy.
    de Biase S; Gigli GL; Valente M; Merlino G
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):459-68. PubMed ID: 24479852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium.
    Simoens S
    J Med Econ; 2011; 14(3):299-304. PubMed ID: 21488712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
    Patsalos PN; Berry DJ
    Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK).
    Flores L; Kemp S; Colbeck K; Moran N; Quirk J; Ramkolea P; von Oertzen TJ; Nashef L; Richardson MP; Goulding P; Elwes R
    Seizure; 2012 Sep; 21(7):512-7. PubMed ID: 22698379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy.
    Kellinghaus C; Berning S; Besselmann M
    Epilepsy Behav; 2009 Feb; 14(2):429-31. PubMed ID: 19130901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous lacosamide--an effective add-on treatment of refractory status epilepticus.
    Albers JM; Möddel G; Dittrich R; Steidl C; Suntrup S; Ringelstein EB; Dziewas R
    Seizure; 2011 Jun; 20(5):428-30. PubMed ID: 21354831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current understanding of the mechanism of action of the antiepileptic drug lacosamide.
    Rogawski MA; Tofighy A; White HS; Matagne A; Wolff C
    Epilepsy Res; 2015 Feb; 110():189-205. PubMed ID: 25616473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.
    Ben-Menachem E
    Drugs Today (Barc); 2008 Jan; 44(1):35-40. PubMed ID: 18301802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
    Wymer JP; Simpson J; Sen D; Bongardt S;
    Clin J Pain; 2009 Jun; 25(5):376-85. PubMed ID: 19454870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrioventricular block following lacosamide intoxication.
    Krause LU; Brodowski KO; Kellinghaus C
    Epilepsy Behav; 2011 Apr; 20(4):725-7. PubMed ID: 21411374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction to zonisamide.
    Baulac M
    Epilepsy Res; 2006 Feb; 68 Suppl 2():S3-9. PubMed ID: 16413170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac safety of lacosamide: the non-clinical perspective.
    Delaunois A; Colomar A; Depelchin BO; Cornet M
    Acta Neurol Scand; 2015 Nov; 132(5):337-45. PubMed ID: 25903789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro.
    Lees G; Stöhr T; Errington AC
    Neuropharmacology; 2006 Jan; 50(1):98-110. PubMed ID: 16225894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lacosamide--oral administration (Vimpat) ].
    Duh D; Peeters S
    J Pharm Belg; 2011 Mar; (1):25-6. PubMed ID: 21473129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.